Drug intelligence / Profile preview

YJJS-71

Development stage: Preclinical
Lead developer: Humanwell Healthcare
Modality: Small Molecules

Overview

YJJS-71 is a small molecule drug candidate being developed by Wuhan Humanwell Hi-Tech Industry as a novel skeletal muscle relaxant. It is currently in the preclinical or early stages of development. The drug is intended for use in conditions requiring skeletal muscle relaxation, which may include the management of muscle spasms or as an adjunct in surgical anesthesia. Specific details regarding its molecular target or mechanism of action have not been publicly disclosed by the developer.

Other names: YJJS-71制剂及原料药

Beyond the preview

Go deeper on YJJS-71.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YJJS-71.

Explore the full profile